Memorial Sloan-Kettering | GenomeWeb

Memorial Sloan-Kettering

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

This Week in Cell

In Cell this week: double-strand breaks in the mouse genome, metabolomic features of yeast deletion strains, and more.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.

Though the results are preliminary, they suggest that a simpler method that doesn't require isolation of CTCs could potentially be as effective as current CTC-based approaches for AR-V7 testing.

Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.

Immunotherapy Buzz

The New York Times looks at immunotherapy and its use in cancer treatment.

The partners will focus on microbiome drugs for cancer patients undergoing hematopoietic stem cell transplantation or receiving checkpoint inhibitors.

Some 20 percent of 650 clinical germlines analyzed since the project launched last year have had at least one variant associated with increased cancer risk.

The institute will combine expertise from six cancer centers in the US in order to drive research and drug development in cancer immunotherapy. 

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.